Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN

Wasatch Advisors LP increased its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 27.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,590,251 shares of the biotechnology company’s stock after acquiring an additional 346,720 shares during the period. Repligen makes up 1.4% of Wasatch Advisors LP’s investment portfolio, making the stock its 19th largest holding. Wasatch Advisors LP owned about 2.82% of Repligen worth $216,974,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. NewEdge Wealth LLC grew its stake in shares of Repligen by 5.3% in the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after buying an additional 75 shares during the last quarter. UMB Bank n.a. raised its position in shares of Repligen by 13.8% in the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after purchasing an additional 100 shares in the last quarter. Coldstream Capital Management Inc. grew its position in Repligen by 5.3% during the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 101 shares during the last quarter. Finally, Itau Unibanco Holding S.A. increased its stake in Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 104 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 1.0%

NASDAQ RGEN opened at $164.77 on Wednesday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a market capitalization of $9.30 billion, a P/E ratio of 225.71, a price-to-earnings-growth ratio of 2.97 and a beta of 1.03. The stock’s 50-day moving average price is $140.11 and its 200-day moving average price is $131.05.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on RGEN shares. Evercore reiterated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. Wells Fargo & Company upped their price objective on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Roth Capital assumed coverage on Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 target price for the company. Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Finally, Barclays increased their price objective on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $166.43.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.